Search
for
Sort by
Research 301–330 of 1000+
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Hidradenitis suppurativa secondary to treatment with a gamma secretase inhibitor
- Effect of a Benign Prostatic Hyperplasia (BPH) Xenobiotic - Croton membranaceus Müll.Arg. Root Extract on CYP1A2, CYP3A4, CYP2D6, and GSTM1 Drug Metabolizing Enzymes in Rat Model
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- 1316 Aqueous extract of Mentha suaveolens induces Nrf-2 activation and expression of antioxidant and detoxifying enzymes in human keratinocyte HaCaT
- Incidence of alopecia from endocrine therapies in cancer
- Efficacy and safety of docetaxel in the elderly
- Men??s Health
- New agents for cancer chemoprevention
- Liposomes in cancer therapy
- Analysis of metabolic characteristics of epristeride in zebrafish based on LC-Q-TOF MS and its potential applications in doping control
- Docetaxel.
- The PDGF/PDGFR pathway as a drug target
- Anthracycline analogs The past, present, and future
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- WNT Signaling in Disease
- Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
- Characterization of the in vitro, ex vivo, and in vivo Efficacy of the Antimicrobial Peptide DPK-060 Used for Topical Treatment
- Treatment of chemotherapy-induced alopecia
- Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Redefining hormone resistance in prostate cancer
- Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- Role of liposomal anthracyclines in the treatment of multiple myeloma
- Targeted therapy in melanoma
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Effective and economical cell therapy for hair regeneration